Lead sponsor
BioXcel Therapeutics Inc
4 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
4
Trials led
0
Ongoing
269
Total enrollment
15
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1/2
1
Phase 2
1
Phase 3
2
Trials by status
Completed
2
Terminated
2
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)Alzheimer's diseasePh 3Completed151
Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)Alzheimer's diseasePh 3Terminated13
An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaMultiple dementia etiologiesPh 2Terminated5